The drug is under distribution and will be in pharmacies by end of the month, said Vikrant Shrotriya, Novo Nordisk's India managing director. Wegovy will be launched in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.

Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while losing weight, offering a potential solution to one of the key problems that’s emerged with popular obesity shots.

Novo Nordisk is ending a deal with telehealth company Hims & Hers, saying Monday that Hims has been engaging in “illegal mass compounding” of GLP-1 obesity treatments and “deceptive marketing.”